Clinical Trial Update: ABI-007 in Taxol Resistant Patients With Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update on ABI-007 (Abraxane) in taxol-resistant metastatic breast cancer; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Abraxane (paclitaxel albumin-bound)

Snippet

Sponsor: Celgene Corporation | Conditions: Breast Neoplasms, Metastases, Neoplasm | Phase 2 | Status: COMPLETED